We use cookies to customise content for your viewing and for analytics. If you continue to browse this website, we will assume that you are happy to receive all our cookies. For further information, please read our cookie policy.
Vivanco-Suarez J, Dibas M, Lopes DK, et al.
Safety and Effectiveness Assessment of the Surpass Evolve (SEASE): A Post-Market International Multicenter Study
73%
Complete occlusion rate at 10.2 months
| Number of patients | 305 |
| Number of aneurysms | 322 |
| Major stroke | 2% (6/293) |
| Procedure-related mortality | 0.7% (2/293) |
| Severe parent vessel stenosis (≥70%) | 1.4% (3/211) |
This Investigator Initiated Study was funded wholly or in part by Stryker. The funding source was not involved in study design, monitoring, data collection, statistical analysis, interpretation of results, or manuscript writing.
Journal of NeuroInterventional Surgery | 2024
Vivanco-Suarez J, Dibas M, Lopes DK, et al. Safety and effectiveness assessment of the surpass evolve (SEASE): a post-market international multicenter study. J Neurointerv Surg. Published online April 25, 2024. doi:10.1136/jnis-2024-021503
Stryker or its affiliated entities own, use, or have applied for the following trademarks or service marks: Stryker, Surpass Evolve. All other trademarks are trademarks of their respective owners or holders.
Information contained herein for use outside the US only.
AP004693 v1.0